Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparison of the Efficacy and Safety of Cilnidipine 10mg/Valsartan 160mg Combination Therapy, Cilnidipine 5mg/Valsartan 160mg Combination Therapy and Valsartan 160mg Monotherapy in Hypertensive Patients Inadequately Controlled With Valsartan 160mg Monotherapy: a Multicenter, Randomized, Double Blind Phase III Study

NCT02145104 is registered in ClinicalTrials.gov with IlDong Pharmaceutical Co Ltd as lead sponsor.

NCT NCT02145104
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02145104 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparison of the Efficacy and Safety of Cilnidipine 10mg/Valsartan 160mg Combination Therapy, Cilnidipine 5mg/Valsartan 160mg Combination Therapy and Valsartan 160mg Monotherapy in Hypertensive Patients Inadequately Controlled With Valsartan 160mg Monotherapy: a Multicenter, Randomized, Double Blind Phase III Study
Lead sponsor
IlDong Pharmaceutical Co Ltd
Phase
Phase 3
Overall status
Completed
Start date
June 17, 2014
Completion date
September 29, 2016
Enrollment
286 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension